LOGIN  |  REGISTER
Terns Pharmaceuticals

Forager Capital Management’s 120% Premium for Quipt Home Medical Would Set M&A Benchmark; Board’s Inaction Erodes Shareholder IRR

September 10, 2025 | Last Trade: US$3.52 0.005 -0.14

BIRMINGHAM, Ala., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Forager Capital Management (“Forager”), one of the largest shareholders of Quipt Home Medical Corp. (“Quipt”) (NASDAQ: QIPT; TSX: QIPT), with beneficial ownership of 9.7% of the outstanding shares, issued the following statement:

“On May 17, 2025 — nearly sixteen weeks ago — Forager submitted an offer to acquire Quipt for $3.10 per share in cash (the “May Offer”). Had Quipt’s Board constructively engaged, the transaction could have been completed by now under the timeline outlined in the May Offer. Shareholders would have locked in a 120% return in under six months — a gain that could have already been redeployed into new opportunities. Every day the Board delays further reduces the IRR for shareholders, a key metric by which performance is judged.

For context, Houlihan Lokey reported that take-private transactions in 2024 saw an average premium of 37.5%, with a peak premium of 106%.1 Forager’s offer — a 120% premium to Quipt’s unaffected share price prior to the May Offer — would exceed every transaction in the report and is more than three times the average.

We remain committed to pursuing a transaction that delivers immediate and compelling value to all Quipt shareholders. We reiterate our willingness to improve our offer upon constructive engagement from the Board.”

Contact:

Johnny Wilhelm
Partner, Forager Capital Management, LLC
205-383-4763
This email address is being protected from spambots. You need JavaScript enabled to view it. 

1 Source: Houlihan Lokey’s 2024 Going Private Transactions Study published in May 2025.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page